McKinsey & Company pays $650M to settle charges linked to boosting opioid sales for Purdue Pharma.

McKinsey & Company agreed to pay $650 million to settle federal charges related to its work with opioid maker Purdue Pharma, which helped boost sales of OxyContin. The deal avoids criminal prosecution if McKinsey adheres to conditions, including not working on controlled substances for five years. Former McKinsey partner Martin Elling agreed to plead guilty to obstruction of justice. Purdue paid McKinsey over $93 million since 2006 for services that included strategies to increase OxyContin sales, contributing to the U.S. opioid crisis.

3 months ago
92 Articles